福建医药杂志
福建醫藥雜誌
복건의약잡지
FUJIAN MEDICAL JOURNAL
2014年
5期
60-61,84
,共3页
隐匿性甲状腺乳头状癌%BRAF基因%CD5 6
隱匿性甲狀腺乳頭狀癌%BRAF基因%CD5 6
은닉성갑상선유두상암%BRAF기인%CD5 6
occult thyroid papillary carcinoma%BRAF gene mutation%CD5 6
目的:通过隐匿性甲状腺乳头状癌中 BRAF 基因突变与 CD56蛋白表达的比较,探讨 CD56蛋白缺失表达在隐匿性甲状腺乳头状癌中的意义。方法选取明确诊断隐匿性甲状腺乳头状癌的155例,通过免疫组化的方法进行 CD56蛋白表达的检测,然后分别对表达阳性和阴性的病例进行荧光PCR法的BRAF基因突变的检测,并对两组 BRAF基因突变率进行统计学分析。结果127例隐匿性甲状腺乳头状癌中 CD56蛋白表达阴性,其 BRAF基因突变率为82%;CD56表达阳性的28例,其BRAF基因突变率为32.1%;两组间比较 BRAF基因突变率差异有统计学意义(P<0.01)。结论 CD56的缺失表达可为隐匿性甲状腺乳头状癌的诊断提供依据。
目的:通過隱匿性甲狀腺乳頭狀癌中 BRAF 基因突變與 CD56蛋白錶達的比較,探討 CD56蛋白缺失錶達在隱匿性甲狀腺乳頭狀癌中的意義。方法選取明確診斷隱匿性甲狀腺乳頭狀癌的155例,通過免疫組化的方法進行 CD56蛋白錶達的檢測,然後分彆對錶達暘性和陰性的病例進行熒光PCR法的BRAF基因突變的檢測,併對兩組 BRAF基因突變率進行統計學分析。結果127例隱匿性甲狀腺乳頭狀癌中 CD56蛋白錶達陰性,其 BRAF基因突變率為82%;CD56錶達暘性的28例,其BRAF基因突變率為32.1%;兩組間比較 BRAF基因突變率差異有統計學意義(P<0.01)。結論 CD56的缺失錶達可為隱匿性甲狀腺乳頭狀癌的診斷提供依據。
목적:통과은닉성갑상선유두상암중 BRAF 기인돌변여 CD56단백표체적비교,탐토 CD56단백결실표체재은닉성갑상선유두상암중적의의。방법선취명학진단은닉성갑상선유두상암적155례,통과면역조화적방법진행 CD56단백표체적검측,연후분별대표체양성화음성적병례진행형광PCR법적BRAF기인돌변적검측,병대량조 BRAF기인돌변솔진행통계학분석。결과127례은닉성갑상선유두상암중 CD56단백표체음성,기 BRAF기인돌변솔위82%;CD56표체양성적28례,기BRAF기인돌변솔위32.1%;량조간비교 BRAF기인돌변솔차이유통계학의의(P<0.01)。결론 CD56적결실표체가위은닉성갑상선유두상암적진단제공의거。
Objective To discusses the meaning of loss of CD56 protein expression in the occult thyroid papillary carcino-ma by the comparison of BRAF gene mutation and CD5 6 protein expression.Methods CD5 6 protein expression was detected in 1 5 5 cases of occult thyroid papillary carcinoma by immunohistochemical methods and BRAF gene mutation was detected by fluo-rescence PCR method respectively in the cases of positive and negative,and statistical analysis was made for the two groups of BRAF mutation rate.Results CD56 expression was negative in 127 cases of occult thyroid papillary carcinoma,which BRAF gene mutation rate was 82%;CD56 expression was positive in 28 cases of occult thyroid papillary carcinoma,which BRAF gene mutation rate is 32.1%;there was statistic significance for BRAF gene mutation rate between the two groups (P< 0.01). Conclusion The lack of CD5 6 expression may provide the reference for the diagnosis of occult thyroid papillary carcinoma.